Details

Autor(en) / Beteiligte

• Chang, Jiang
• Zhang, Yaodong
• Zhou, Tao
• Qiao, Qian
• Shan, Jijun
• Chen, Yananlan
• Jiang, Wangjie
• Wang, Yirui
• Liu, Shuochen
• Wang, Yuming
• Yu, Yue
• Li, Changxian
• Li, Xiangcheng

Titel

RBM10 C761Y mutation induced oncogenic ASPM isoforms and regulated [beta]-catenin signaling in cholangiocarcinoma

Ist Teil von

• Journal of experimental & clinical cancer research, 2024-04, Vol.43 (1)

Ort / Verlag

BioMed Central Ltd

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Background Cholangiocarcinoma (CCA) comprises a heterogeneous group of biliary tract cancer. Our previous CCA mutation pattern study focused on genes in the post-transcription modification process, among which the alternative splicing factor RBM10 captured our attention. However, the roles of RBM10 wild type and mutations in CCA remain unclear. Methods RBM10 mutation spectrum in CCA was clarified using our initial data and other CCA genomic datasets from domestic and international sources. Real-time PCR and tissue microarray were used to detect RBM10 clinical association. Function assays were conducted to investigate the effects of RBM10 wild type and mutations on CCA. RNA sequencing was to investigate the changes in alternative splicing events in the mutation group compared to the wild-type group. Minigene splicing reporter and interaction assays were performed to elucidate the mechanism of mutation influence on alternative splicing events. Results RBM10 mutations were more common in Chinese CCA populations and exhibited more protein truncation variants. RBM10 exerted a tumor suppressive effect in CCA and correlated with favorable prognosis of CCA patients. The overexpression of wild-type RBM10 enhanced the ASPM exon18 exon skipping event interacting with SRSF2. The C761Y mutation in the C.sub.2H.sub.2-type zinc finger domain impaired its interaction with SRSF2, resulting in a loss-of-function mutation. Elevated ASPM203 stabilized DVL2 and enhanced [beta]-catenin signaling, which promoted CCA progression. Conclusions Our results showed that RBM10.sup.C761Y-modulated ASPM203 promoted CCA progression in a Wnt/[beta]-catenin signaling-dependent manner. This study may enhance the understanding of the regulatory mechanisms that link mutation-altering splicing variants to CCA. Keywords: RBM10, Mutation, Alternative splicing, ASPM, Cholangiocarcinoma